Cargando…
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Neurofibrillary pathology comprised of pathological tau protein is closely tied to a range of neurodegenerative disorders, the most common of which is Alzheimer’s disease. While they are individually rarer, a range of other disorders, the tauopathies (including Pick’s disease, progressive supranucle...
Autores principales: | Novak, Petr, Kontsekova, Eva, Zilka, Norbert, Novak, Michal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224648/ https://www.ncbi.nlm.nih.gov/pubmed/30450030 http://dx.doi.org/10.3389/fnins.2018.00798 |
Ejemplares similares
-
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
por: Kontsekova, Eva, et al.
Publicado: (2014) -
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease
por: Kontsekova, Eva, et al.
Publicado: (2014) -
Truncated tau deregulates synaptic markers in rat model for human tauopathy
por: Jadhav, Santosh, et al.
Publicado: (2015) -
A walk through tau therapeutic strategies
por: Jadhav, Santosh, et al.
Publicado: (2019) -
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease
por: Novak, Petr, et al.
Publicado: (2018)